Home › Triple-Negative Breast Cancer › Pennsylvania
Triple-Negative Breast Cancer clinical trials in Pennsylvania
23 studies for Triple-Negative Breast Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03606967A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
- Cancer Care Associates Of York ( Site 9517), York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06393374Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Lancaster General Health, Lancaster
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- UPMC Magee-Womens Hospital, Pittsburgh
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07115043The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- UPMC, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Lehigh Valley Health Network, Allentown
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
- Local Institution - 0360, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Pennsylvania (U Penn), Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT04434040ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
- UPMC Hillman Cancer, Pittsburgh
RecruitingObservational study
Ages 18 and older · Women · Updated May 1, 2026 · NCT07332975Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT04468061Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- Lehigh Valley Health Network, Allentown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT03808337Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
- Thomas Jefferson University Hospital, Philadelphia
Recruiting
Ages 40 and older · All sexes · Updated Jan 23, 2026 · NCT04959474Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06249048Role of the Immune Environment in Response to Therapy in Breast Cancer
- Abramson Cancer Center, Philadelphia
RecruitingObservational study
Ages 18 and older · Women · Updated Jul 8, 2025 · NCT05396612CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Cancer Care Associates of York, York
RecruitingObservational study
Ages 18 and older · Women · Updated Jan 7, 2025 · NCT06230185From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.